PR Newswire·Nov 6, 2026, 10:04 AM ET

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

Halozyme Therapeutics projects zero to minimal royalty revenue impact through at least 2035 following the November 5, 2026, CMS final rule on the Medicare Drug Price Negotiation Program.
The company states there will be no projected impact on its ability to execute new ENHANZE® partnership agreements due to the drug delivery technology's patient experience benefits.
The outlook relies on final rule affirmations that orphan drug protections remain applicable and that biosimilar entry impacts Program eligibility.
Halozyme's ENHANZE® technology is licensed to major partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, Merus N.V., GSK, & Incyte across over 100 global markets.
The company expanded its portfolio with Hypercon™ & Aerocon™ technologies to enable hyperconcentration of biologics, licensed to partners such as Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, & Oruka Therapeutics.
Halozyme commercializes proprietary drug-device products Hylenex® & XYOSTED® while maintaining development programs with Teva Pharmaceuticals & McDermott Laboratories Limited.
The press release includes forward-looking statements regarding financial performance, royalty revenues, & partnership expectations subject to risks like CMS guidance changes, biosimilar launches, & competitive conditions.